Dr. Hollingshead has served as our President and Chief Executive Officer since June 1, 2022 and has served on our Board of Directors since July 2019. From July 2020 to May 2022, he served as President of the Sleep and Respiratory Care “SRC” business at ResMed Inc., a publicly held global medical technology company focused on the treatment of sleep-related breathing disorders. As President of ResMed’s SRC business, Dr. Hollingshead led ResMed’s transformation from a traditional medical hardware technology business to a SaaS-based digital solutions and services business. From 2011 to 2017, he held numerous positions at ResMed, including President, Americas, Chief Strategy Officer, and President, Ventures & Initiatives. Previously, Dr. Hollingshead spent nearly two decades in strategy consulting across a range of industries including biotech, high-tech, and telecommunications. Prior, he was a senior partner in the Strategy and Life Sciences practices at Deloitte Consulting and also served as Managing Partner at Monitor Group, a U.S. strategy consulting firm, including serving in various global roles, including Founder and Managing Partner and European Marketing Strategy Practice in the U.K. and Office Managing Partner in Istanbul. Dr. Hollingshead holds a Bachelor of Arts in History and International Relations with Highest Distinction from Stanford University, and a Master’s Degree and Ph.D. in Political Science from the University of California, Berkeley, where he was awarded a graduate student Fellowship by the National Science Foundation.
Board of Directors
Dr. Borio has served on our Board of Directors since October 2021. She is a venture partner at ARCH Venture Partners where she advises on new investment opportunities related to biologics manufacturing, clinical trials, novel therapies, and areas with large unmet clinical needs. She also serves on the Board of Directors of Eagle Pharmaceuticals, Inc. From 2019 to 2020, she was Senior Vice President at In-Q-Tel, an independent, non-profit, strategic investment firm. From 2017 to 2019, she was Director for Medical and Biodefense Preparedness Policy at the National Security Council. While at the U.S. Food and Drug Administration from 2009 to 2017, Dr. Borio held roles of increasing responsibility, including Acting Chief Scientist and Assistant Commissioner for Counterterrorism Policy. She helped develop and execute the FDA’s medical countermeasures and public health responses to the 2009 H1N1 flu pandemic, the 2014 Ebola epidemic, and the 2015 Zika outbreak. She also served on the World Health Organization’s Emergency Preparedness and Response Scientific Advisory Group.
Most recently, Dr. Borio served as a member of the President’s Transition COVID-19 Advisory Board. Dr. Borio is a practicing physician at Johns Hopkins Hospital and a senior fellow for Global Health at the Council on Foreign Relations. She earned a Doctor of Medicine from George Washington University School of Medicine and a Bachelor of Science in Zoology from George Washington University. With her medical and public health background, as well as her experience at the FDA, Dr. Borio brings exceptional regulatory and scientific perspective.
Dr. Frederick has served on our Board of Directors since October 2020. He is the president of Howard University and serves as the Charles R. Drew Endowed Chair of Surgery at Howard University’s College of Medicine. Prior to being appointed president in 2014, Dr. Frederick served as Howard University’s Provost and Chief Academic Officer. Dr. Frederick also serves as an independent director on the Board of Directors of Workday.
Dr. Frederick is a practicing surgeon, distinguished researcher and scholar, and the author of numerous peer-reviewed articles, book chapters, abstracts, and editorials. He has received several awards for his scholarship and public service and continues lectures to medical students and residents of Howard’s College of Medicine. He is a fellow of the American College of Surgeons and belongs to numerous surgical organizations, including the American Surgical Association.
As a widely recognized expert on disparities in healthcare and medical education, his medical research focuses on narrowing racial, ethnic, and gender disparities in cancer care outcomes among African Americans and other underrepresented groups. Dr. Frederick has served as the principal investigator for major collaborations with the National Cancer Institute and Johns Hopkins University, as well as several national minority-serving oncology programs.
He received his Bachelor of Science, Doctor of Medicine, and Master of Business Administration from Howard University. Dr. Frederick also serves on the Board of Directors of Humana Inc., Forma Therapeutics Holdings, Inc., Mutual of America Life Insurance Co. and Tempus Labs, Inc., as well as other privately held companies and charitable organizations. Dr. Frederick’s vast experience in medical research, healthcare academics, and business administration brings valuable insights to Insulet’s Board.
Dr. Hopfield, who is NACD Directorship certified, has served on our Board of Directors since July 2015 and served as our Lead Independent Director from August 2016 to January 2019. Dr. Hopfield serves on the Boards of Directors of Berkeley Lights, Editas Medicine (where she currently serves as Lead Independent Director) and Maravai and is a former Trustee and Chair of the Joslin Diabetes Center. Dr. Hopfield is a distinguished healthcare executive and diabetes expert with over two decades of experience in the medical and healthcare fields. She is a strategic advisor and investor in healthcare and technology firms seeking to commercialize innovative intellectual property. From 1995 to 2009, Dr. Hopfield was a Partner of McKinsey & Company in their global pharmaceuticals and medical devices practice and she served clients across pharmaceutical, biotech, medical device and consumer industries with a focus on strategy, R&D management and marketing. Dr. Hopfield also previously held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing. She earned a Bachelor of Science from Yale College, a Master of Business Administration from Harvard Graduate School of Business Administration as a Baker Scholar, and a Doctor of Philosophy in Neuroscience/Biochemistry from The Rockefeller University. Dr. Hopfield brings proven experience in the diabetes field, along with vast executive and consulting experience in the healthcare, pharmaceutical, and medical device industries.
Mr. Minogue has served on our Board of Directors since August 2017. Since 2004, Mr. Minogue has served as Chairman, President and Chief Executive Officer of Abiomed, Inc., a global leader in healthcare technology and innovation. Prior to joining Abiomed, he spent 11 years with General Electric Healthcare, where he held numerous leadership roles and holds three patents. In addition to serving on the Board of Abiomed, Mr. Minogue currently serves as Chairman of the medical device industry association Board of Directors for the Advanced Medical Technology Association (AdvaMed). He previously served on the Board of Directors of LifeCell, Bioventus and the Medical Device Innovation Consortium (MDIC) and as the Chairman of the Governor’s Advisory Council on Veterans’ Services for the Commonwealth of Massachusetts. Mr. Minogue cofounded the Mike and Renee Minogue Foundation and the Mentoring Veterans Program (MedTechVets), a 501(c)(3) nonprofit organization that helps military veterans network with industry mentors to discover career opportunities in the medtech industry; he serves on the board of directors after serving as Chairman for eight years. Mr. Minogue served as an officer in the U.S. Army, receiving multiple distinctions, including Airborne, Ranger, Desert Storm veteran and a Bronze Star. He received a Bachelor of Science in Engineering Management from the United States Military Academy at West Point and a Master of Business Administration from the University of Chicago. Mr. Minogue brings distinguished senior executive leadership experience, as well as direct experience driving innovation and product development.
Ms. Nevinny has served on our Board of Directors since January 2019. Ms. Nevinny is a co-founder of Avestria Ventures, a venture capital firm focused on early stage investments in women’s health care and women in Lifesciences. She has served as a Partner of Avestria since 2019. She also serves as General Partner at LMNVC, a seed venture fund making early-round investments in start-up companies that have products or provide services to improve quality of life, including health and wellness oriented businesses. From 2003 to 2010, she served in various roles at Edwards Lifesciences Corporation, including General Manager – Cardiac Surgery Systems, President of Global Operations, and Chief Financial Officer and Treasurer. During this time, Ms. Nevinny was responsible for global manufacturing, quality and supply chain operations, as well as oversight of core operating units including finance, IT, internal audit and risk management. Prior to joining Edwards Lifesciences Corporation, Ms. Nevinny held various finance and investment banking positions. Ms. Nevinny currently serves on the Board of Directors of Restorsea LLC. She previously served on the Board of privately-held nVision Medical Corp., as well as public company Boards, including Avanir Pharmaceuticals, Inc., Neurocrine Biosciences and Onyx Pharmaceuticals, Inc., and chaired the Audit Committees for Avanir, Neurocrine and Onyx. Ms. Nevinny holds a Bachelor of Science in Industrial Engineering from Stanford University and a Master of Business Administration from Harvard Business School. Ms. Nevinny brings considerable public board experience and a breadth of first-hand experience managing complex global finance, logistics, regulatory and manufacturing operations, which are directly relevant to our business.
Ms. Petrovic has served on our Board of Directors since September 2018. She also serves as an advisor to the Company since June 1, 2022. She also serves on the Board of Directors of Exact Sciences Corporation. Ms. Petrovic has held various executive positions at Insulet, including, from January 2019 to May 2022, President and Chief Executive Officer; from October 2016 to December 2018, President and Chief Operating Officer; from February 2016 to October 2016, Executive Vice President and President, Diabetes Products; and from February 2015 to February 2016, Chief Commercial Officer. From 2013 to 2015, Ms. Petrovic served as President and Chief Executive Officer of Clinical Innovations, LLC, a developer and manufacturer of medical devices and diagnostics for women’s health. From 2000 to 2013, she served in a number of key roles at Hologic, Inc. and Cytyc Corporation, which merged with Hologic in October 2007, including Vice President and General Manager of Hologic’s GYN Surgical Products division, as well as various sales and marketing leadership roles in the U.S. and Europe. Ms. Petrovic earned her Bachelor of Science in Biology from the University of Wisconsin. Ms. Petrovic brings to the Board deep insight into the Company’s strategy, operations and mission as well as decades of experience as an executive in the medical device industry.
Mr. Scannell has served on our Board of Directors since August 2014 and as our Board Chair since January 1, 2019. He also serves on the Board of Directors of Novocure, Renalytix and AeroClean Technologies. Since October 2021, he has served as an Executive Advisor at Stryker Corporation, one of the world's leading medical technology companies that offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. From August 2018 to September 2021, he served as the President and Chief Operating Officer at Stryker, and from 2009 to August 2018, he served as a Group President and oversaw Stryker’s MedSurg and Neurotechnology divisions. From 1990 to 2009, Mr. Scannell served in various roles at Stryker, including a range of sales and marketing leadership roles, Vice President and General Manager of its Biotech division and President of its Spine business. Mr. Scannell holds a Bachelor of Business Administration and a Master of Business Administration from the University of Notre Dame. He brings extensive strategic, organizational, and operational skills and experience.
Elizabeth Weatherman has served on our Board of Directors since February 2022. She has been a Special Limited Partner of Warburg Pincus since January 2016. Ms. Weatherman joined Warburg Pincus in 1988 and led the firm’s Healthcare Group from 2008 to 2015 and was previously a Managing Director and a member of the firm’s Executive Management Group. Ms. Weatherman currently serves as a director of Nevro Corporation, Silk Road Medical, Inc., and Vapotherm, Inc., all of which are publicly traded medical device companies, and she was previously a board member of Wright Medical Group, N.V. She serves as a trustee of Stanford University and as a trustee and chair of the Investment Committee of Mount Holyoke College. Ms. Weatherman earned a Bachelor of Arts in English from Mount Holyoke College and a Master of Business Administration from the Stanford Graduate School of Business. With her extensive healthcare investment knowledge, as well as her experience on the boards of other public medical device companies, Ms. Weatherman brings strong strategic and governance perspectives.